Roche's U.S. gRED research head to retire, be replaced by MIT's Regev

ZURICH (Reuters) - Roche said Monday it has hired a Massachusetts Institute of Technology (MIT) professor as the new head of the Swiss drugmaker's U.S. research arm that was responsible for some of the company's best-selling medicines of the last few decades.Aviv Regev, an Israeli-American born in 1971, replaces the current head of Roche's Genentech Research and Early Development (gRED), Michael Varney. He is retiring after holding the post for five years. gRED, based near San Francisco, was..